CTX340
/ CRISPR Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 12, 2026
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
(clinicaltrials.gov)
- P1/2 | N=69 | Recruiting | Sponsor: CRISPR Therapeutics AG
First-in-human • New P1/2 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1